Pharmacological and clinical dilemmas of prescribing in co‐morbid adult attention‐deficit/hyperactivity disorder and addiction
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
The present article reviews whether available efficacy and safety data support the pharmacological treatment of adult attention‐deficit/hyperactivity disorder (ADHD) in patients with concurrent substance use disorders (SUD). Arguments for and against treating adult ADHD with active SUD are discussed. Findings from 19 large open studies and controlled clinical trials show that the use of atomoxetine or extended‐release methylphenidate formulations, together with psychological therapy, yield promising though inconclusive results about short term efficacy of these drugs in the treatment of adult ADHD in patients with SUD and no other severe mental disorders. However, the efficacy of these drugs is scant or lacking for treating concurrent SUD. No serious safety issues have been associated with these drugs in patients with co‐morbid SUD‐ADHD, given their low risk of abuse and favourable side effect and drug–drug interaction profile. The decision to treat adult ADHD in the context of active SUD depends on various factors, some directly related to SUD‐ADHD co‐morbidity (e.g. degree of diagnostic uncertainty for ADHD) and other factors related to the clinical expertise of the medical staff and availability of adequate resources (e.g. the means to monitor compliance with pharmacological treatment). Our recommendation is that clinical decisions be individualized and based on a careful analysis of the advantages and disadvantages of pharmacological treatment for ADHD on a case‐by‐case basis in the context of active SUD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NEURAL MECHANISMS OF ADDICTION: The Role of Reward-Related Learning and Memory
Hyman, S. E., Malenka, R. C., & Nestler, E. J. (2006) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.29.051605.113009 · Cited by 2,647
Attentional bias in addictive behaviors: A review of its development, causes, and consequences
FIELD, M., & COX, W. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.03.030 · Cited by 1,376
Dopamine in drug abuse and addiction: results from imaging studies and treatment implications
Volkow, N. D., Fowler, J. S., Wang, G.-J., & Swanson, J. M. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001507 · Cited by 1,101
Kooij, S. J., Bejerot, S., Blackwell, A., Caci, H., Casas-Brugué, M., Carpentier, P. J., Edvinsson, D., Fayyad, J., Foeken, K., Fitzgerald, M., et al. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-67 · Cited by 928
Wilens, T. E., Faraone, S. V., Biederman, J., & Gunawardene, S. (2003) · Pediatrics · doi:10.1542/peds.111.1.179 · Cited by 872
del Campo, N., Chamberlain, S. R., Sahakian, B. J., & Robbins, T. W. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.02.036 · Cited by 685
Impulsivity, frontal lobes and risk for addiction
Crews, F. T., & Boettiger, C. A. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.04.018 · Cited by 679
Young adult follow‐up of hyperactive children: antisocial activities and drug use
Barkley, R. A., Fischer, M., Smallish, L., & Fletcher, K. (2004) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2004.00214.x · Cited by 567
van Emmerik-van Oortmerssen, K., van de Glind, G., van den Brink, W., Smit, F., Crunelle, C. L., Swets, M., & Schoevers, R. A. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.12.007 · Cited by 535
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.11.1652 · Cited by 528
Charach, A., Yeung, E., Climans, T., & Lillie, E. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.09.019 · Cited by 482
Elkins, I. J., McGue, M., & Iacono, W. G. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1145 · Cited by 480
Kollins, S. H., McClernon, F. J., & Fuemmeler, B. F. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.10.1142 · Cited by 369
Klein, R. G. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830240023003 · Cited by 349
Faraone, S. V., Biederman, J., Spencer, T., Mick, E., Murray, K., Petty, C., Adamson, J. J., & Monuteaux, M. C. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.10.1720 · Cited by 329
Biederman, J., Wilens, T. E., Mick, E., Faraone, S. V., & Spencer, T. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00406-x · Cited by 315
Barkley, R. A., Fischer, M., Smallish, L., & Fletcher, K. (2003) · Pediatrics · doi:10.1542/peds.111.1.97 · Cited by 274
Mannuzza, S., Klein, R. G., Truong, N. L., Moulton, J. L., Roizen, E. R., Howell, K. H., & Castellanos, F. X. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07091465 · Cited by 263
Schubiner, H., Downey, K. K., Arfken, C. L., Johanson, C.-E., Schuster, C. R., Lockhart, N., Edwards, A., Donlin, J., & Pihlgren, E. (2002) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.10.3.286 · Cited by 249
Biederman, J., Monuteaux, M. C., Spencer, T., Wilens, T. E., MacPherson, H. A., & Faraone, S. V. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07091486 · Cited by 239
Levin, F. R., Evans, S. M., Brooks, D. J., & Garawi, F. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.07.004 · Cited by 220
Castells, X., Ramos-Quiroga, J. A., Rigau, D., Bosch, R., Nogueira, M., Vidal, X., & Casas, M. (2011) · CNS Drugs · doi:10.2165/11539440-000000000-00000 · Cited by 197
Distinguishing comorbidity and successful management of adult ADHD
Kooij, J. J. S., Huss, M., Asherson, P., Akehurst, R., Beusterien, K., French, A., Sasané, R., & Hodgkins, P. (2012) · Journal of Attention Disorders · doi:10.1177/1087054711435361 · Cited by 172
Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders
Wilens, T. E., Adler, L. A., Weiss, M. D., Michelson, D., Ramsey, J. L., Moore, R. J., Renard, D., Brady, K. T., Trzepacz, P. T., Schuh, L. M., et al. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.02.009 · Cited by 171
Jasinski, D., & Krishnan, S. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109103113 · Cited by 149
Koesters, M., Becker, T., Kilian, R., Fegert, J., & Weinmann, S. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108092338 · Cited by 142
Flory, K., & Lynam, D. R. (2003) · Clinical Child and Family Psychology Review · doi:10.1023/a:1022260221570 · Cited by 139
Bond, D. J., Hadjipavlou, G., Lam, R. W., McIntyre, R. S., Beaulieu, S., Schaffer, A., & Weiss, M. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400104 · Cited by 133
Bupropion Treatment for Cocaine Abuse and Adult Attention-Deficit/Hyperactivity Disorder
Levin, F. R., Evans, S. M., McDowell, D. M., Brooks, D. J., & Nunes, E. (2002) · Journal of Addictive Diseases · doi:10.1300/j069v21n02_01 · Cited by 102
Abuse liability assessment of atomoxetine in a drug-abusing population
Jasinski, D. R., Faries, D. E., Moore, R. J., Schuh, L. M., & Allen, A. J. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.01.008 · Cited by 87
Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: A pilot study
Konstenius, M., Jayaram-Lindström, N., Beck, O., & Franck, J. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.11.006 · Cited by 83
Kalechstein, A. D., De La Garza, II, & Newton, T. F. (2010) · The American Journal on Addictions · doi:10.1111/j.1521-0391.2010.00052.x · Cited by 67
Santosh, P. J., Sattar, S., & Canagaratnam, M. (2011) · CNS Drugs · doi:10.2165/11593070-000000000-00000 · Cited by 62
Pérez de los Cobos, J., Siñol, N., Puerta, C., Cantillano, V., López Zurita, C., & Trujols, J. (2011) · Psychiatry Research · doi:10.1016/j.psychres.2009.03.019 · Cited by 61
Self-citationSerra-Pinheiro, M. A., Coutinho, E. S. F., Souza, I. S., Pinna, C., Fortes, D., Araújo, C., Szobot, C. M., Rohde, L. A., & Mattos, P. (2013) · Journal of Attention Disorders · doi:10.1177/1087054711435362 · Cited by 43
Hester, R., Lee, N., Pennay, A., Nielsen, S., & Ferris, J. (2010) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0021791 · Cited by 42
Vergara-Moragues, E., González-Saiz, F., Lozano Rojas, O., Bilbao Acedos, I., Fernández Calderón, F., Betanzos Espinosa, P., Verdejo García, A., & Pérez García, M. (2011) · European Addiction Research · doi:10.1159/000329725 · Cited by 22
Cited by
Updated European Consensus Statement on diagnosis and treatment of adult ADHD
Kooij, J. J. S., Bijlenga, D., Salerno, L., Jaeschke, R., Bitter, I., Balázs, J., Thome, J., Dom, G., Kasper, S., Nunes Filipe, C., et al. (2019) · European Psychiatry · doi:10.1016/j.eurpsy.2018.11.001 · Cited by 686
“Immediate-release stimulants should be avoided in patients with ADHD and SUD, whereas OROS-MPH and LDX have lower abuse potential [284].”
BackgroundTreatment strategies for ADHD: an evidence-based guide to select optimal treatment
Caye, A., Swanson, J. M., Coghill, D., & Rohde, L. A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0116-3 · Cited by 303
Psychostimulant drugs for cocaine dependence
Castells, X., Cunill, R., Pérez-Mañá, C., Vidal, X., & Capellà, D. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007380.pub4 · Cited by 110
Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence
Cunill, R., Castells, X., Tobias, A., & Capellà, D. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114544777 · Cited by 78
Philipsen, A., Graf, E., Jans, T., Matthies, S., Borel, P., Colla, M., Gentschow, L., Langner, D., Jacob, C., Groß-Lesch, S., et al. (2014) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-013-0120-z · Cited by 44
Metadata
- Authors
- Pérez de los Cobos, J., Siñol, N., Pérez, V., & Trujols, J.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2014-01-22
- Volume
- 77
- Issue
- 2
- Pages
- 337-356
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1563471420
- Cited by
- 35
- References
- 37
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.